F13B Antibody

What is F13B and why is it important in biomedical research?

F13B encodes the B subunit of coagulation factor XIII, which is essential for blood clot stabilization. The B subunit acts as a carrier for the active A subunit, ensuring its stability and proper function in the coagulation cascade . Research has identified F13B as potentially significant in various cancers, including clear cell renal cell carcinoma, medulloblastoma, and colorectal cancer . Additionally, studies have demonstrated its role in angiogenesis regulation through the HIF-1α/VEGF pathway, making it a critical focus for cancer research .

How does F13B differ from F13A, and what are the implications for antibody selection?

Factor XIII exists as a heterotetramer in plasma (α₂β₂) with F13B being the β subunit, whereas in platelets, only the α₂ unit (F13A) exists . When selecting antibodies, it's critical to understand which subunit you're targeting:

• F13A: The catalytic subunit (M.W. 160,000) that exists as a dimer

• F13B: The carrier subunit that stabilizes F13A in plasma

Antibodies specifically targeting F13A won't cross-react with F13B and vice versa. For example, the monoclonal antibody described in search result "recognizes human Factor XIII A-chain in both reduced and non-reduced forms. It does not react with human Factor XIII B-chain or human Factor XII." This distinction is crucial for experimental design in studies targeting specific subunits of the Factor XIII complex .

What controls should I include when using F13B antibodies in flow cytometry experiments?

When designing flow cytometry experiments with F13B antibodies, controls are essential for proper interpretation. You should include:

• Single stain controls: These must be run every time you perform an experiment, even if repeating the same panel. This is necessary due to potential variations in antibody staining, fluorophore stability, and instrument parameters between experiments .

• Unstained controls: To account for autofluorescence.

• Isotype controls: To detect non-specific binding.

• Positive controls: Samples known to express F13B (e.g., liver samples, as F13B is highly expressed in liver ).

• Negative controls: Samples known not to express F13B.

Without proper controls, particularly single stain controls, you risk creating inaccurate compensation matrices that can lead to false results. As demonstrated in search result , applying old compensation matrices to new samples without new controls can lead to misinterpretation of data due to day-to-day variations in staining intensity and instrument parameters.

How should I validate F13B antibody specificity for my research application?

Thorough validation of F13B antibodies should include:

• Western blotting: Test the antibody on cell/tissue lysates known to express F13B (e.g., liver samples) and compare with negative controls. Verify that the observed molecular weight matches the expected size (approximately 75-76 kDa calculated molecular weight) .

• Immunohistochemistry validation: If using for IHC, test on both positive control tissues (e.g., human liver) and negative control tissues .

• Peptide competition assay: Use the immunizing peptide to block antibody binding and confirm specificity. Many manufacturers offer blocking peptides that correspond to the immunogen used to generate the antibody .

• Cross-reactivity testing: If your research involves multiple species, verify reactivity across relevant species. For example, some F13B antibodies show predicted reactivity with human (100%), mouse (100%), rat (100%), cow (100%), guinea pig (100%), dog (86%), horse (93%), and rabbit (93%) .

• Genetic knockdown/knockout validation: Where possible, use F13B knockdown or knockout samples to confirm antibody specificity.

How can F13B antibodies be used to investigate the role of F13B in cancer progression and angiogenesis?

Recent research has revealed that F13B regulates angiogenesis through the HIF-1α/VEGF pathway and plays a crucial role in hepatocellular carcinoma (HCC) progression . To investigate this role:

• Immunohistochemistry (IHC): Use F13B antibodies to quantify expression levels in tumor tissues versus normal adjacent tissues. This can help establish correlations between F13B expression and clinical outcomes.

• Cell signaling pathway analysis: After F13B overexpression or knockdown, use specific antibodies to analyze the effects on the HIF-1α/VEGF pathway components, including:

  • HIF-1α expression levels

  • VEGFA expression

  • AKT/mTOR pathway activation status

• Functional assays: Combine F13B antibodies with angiogenesis assays:

  • HUVEC tube formation assays

  • Migration and invasion assays

  • Proliferation assays

Research has shown that F13B overexpression suppresses HCC proliferation, migration, and invasion, while its knockdown promotes these processes. F13B also inhibits angiogenesis by downregulating VEGFA and key signaling pathways, including the AKT/mTOR pathway .

What is the significance of F13B genetic polymorphisms in disease risk assessment, and how can antibodies help study these variants?

F13B exhibits significant genetic polymorphisms with unusual patterns of interpopulation differentiation. Three major protein alleles exist, each at high frequency in different populations: allele 1 in Europeans, allele 2 in Africans, and allele 3 in Asians . These polymorphisms demonstrate unusual levels of population differentiation (p=0.003) and an excess of allele-specific, extended haplotype homozygosity within African populations (p=0.0125) .

To study these variants:

• Allele-specific antibodies: Develop antibodies that specifically recognize protein products of different F13B alleles, particularly focusing on the His95Arg substitution that defines allele 2.

• Correlation studies: Use these antibodies to correlate F13B variant expression with disease outcomes. Studies have shown that F13B variability modulates susceptibility and/or survivorship in coronary artery disease (p<0.05) and type II diabetes within coronary artery disease cohorts (p<0.01) .

• Functional characterization: Combine antibody detection with functional assays to determine how these variants affect F13B function in coagulation and angiogenesis.

What are the optimal fixation and antigen retrieval methods for using F13B antibodies in immunohistochemistry?

Based on the available data, for successful F13B immunohistochemistry:

It's worth noting that some antibodies may perform differently depending on the fixation method, so validation with your specific tissue and fixation protocol is recommended.

How do I troubleshoot non-specific binding or weak signal when using F13B antibodies?

Non-specific binding or weak signal can significantly impact experimental results. Troubleshooting strategies include:

For weak signal:

• Antibody concentration: Titrate the antibody to find optimal concentration. For Western blotting, try concentrations between 1:500-1:2000; for IHC-P, try 1:100-1:300 .

• Antigen retrieval optimization: Test different antigen retrieval methods (heat-induced vs. enzymatic) and buffers (citrate buffer pH 6.0 vs. EDTA buffer pH 9.0).

• Incubation conditions: Extend primary antibody incubation time (overnight at 4°C) or use a more sensitive detection system.

• Sample preparation: Ensure proper sample preparation. For Western blotting, check protein loading and transfer efficiency.

For non-specific binding:

• Blocking optimization: Increase blocking time or try different blocking agents (5% BSA, 5% non-fat milk, commercial blocking buffers).

• Washing steps: Increase the number and duration of washing steps.

• Antibody specificity: Confirm antibody specificity using blocking peptides. Some manufacturers provide blocking peptides corresponding to the immunogen used to generate the antibody .

• Secondary antibody cross-reactivity: Test for secondary antibody cross-reactivity by omitting the primary antibody.

• Tissue autofluorescence: For immunofluorescence, treat tissues with Sudan Black B or commercial autofluorescence quenchers.

How should I interpret F13B expression data in relation to other coagulation factors and angiogenesis markers?

When analyzing F13B expression data alongside other coagulation factors and angiogenesis markers, consider:

• Pathway interactions: F13B regulates angiogenesis through the HIF-1α/VEGF pathway . When interpreting F13B expression, correlate it with HIF-1α and VEGF levels to understand the complete signaling cascade.

• Prognostic significance: Higher F13B expression levels are associated with better patient outcomes, including improved progression-free survival (PFS), disease-specific survival (DSS), and disease-free interval (DFI) in hepatocellular carcinoma . Analyze F13B expression in the context of these clinical outcomes.

• Clinical characteristics: F13B expression varies with clinical parameters:

  • Increases with patient age

  • Decreases with higher tumor grades

  • Higher in N0 nodal metastasis group

  • Higher in TP53-NonMutant patients compared to TP53-Mutant patients

• Enriched pathways: Gene Set Enrichment Analysis (GSEA) for F13B revealed associations with nephrogenesis, PPAR signaling pathway, and EGFR tyrosine kinase inhibitor resistance . When interpreting F13B data, consider its role in these pathways.

• Genetic polymorphisms: Different F13B alleles may have different functional implications. Consider genotyping samples to understand how genetic variation influences expression and function .

What statistical approaches are most appropriate for analyzing F13B expression data in cancer studies?

Based on literature examining F13B in cancer, the following statistical approaches are recommended:

• Survival analysis:

  • Cox proportional hazards regression (both univariate and multivariate) to assess F13B as a prognostic factor

  • Kaplan-Meier survival curves with log-rank tests to compare survival differences between high and low F13B expression groups

• Nomogram construction:

  • Develop predictive models incorporating F13B expression with other clinical parameters

  • Validate using C-index (values closer to 1 indicate better predictive ability) and calibration curves

• Correlation analyses:

  • Pearson or Spearman correlation to assess relationships between F13B expression and other molecular markers

  • Point-biserial correlation for dichotomous variables (e.g., presence/absence of metastasis)

• Pathway analysis:

  • Gene Set Enrichment Analysis (GSEA) to identify biological pathways associated with F13B expression

  • Network analysis to understand F13B's position in relevant signaling networks

• Population differentiation statistics:

  • FST analysis to assess population-specific patterns of F13B expression (particularly relevant given the known population stratification of F13B alleles)

  • Extended haplotype homozygosity (EHH) tests like Raw and Rab to detect signals of selection